Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Innoviva, Inc.
  6. Summary
    INVA   US45781M1018

INNOVIVA, INC.

(INVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
16.41(c) 16.51(c) 16.42(c) 16.24(c) 15.93(c) Last
488 819 400 132 410 187 252 475 730 433 Volume
+1.11% +0.61% -0.55% -1.10% -1.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 292 M - -
Net income 2021 - - -
Net cash position 2021 430 M - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 235 M - -
Net income 2022 - - -
Net cash position 2022 630 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 1 107 M 1 107 M -
EV / Sales 2021 2,32x
EV / Sales 2022 2,03x
Nbr of Employees 5
Free-Float 68,0%
More Financials
Company
Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Ratings of Innoviva, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about INNOVIVA, INC.
09/15Health Care Stocks Pare Early Gains As Cyclicals Dominate Afternoon Trade
MT
07/29INNOVIVA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
07/29Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on May 20, 2021.
CI
07/28INNOVIVA, INC. : Results of Operations and Financial Condition, Financial Statements and E..
AQ
07/28INNOVIVA : Q2 Earnings Snapshot
AQ
07/28INNOVIVA : Reports Second Quarter 2021 Financial Results
BU
07/28Innoviva, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell 3000 Value Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) dropped from Russell 2000 Dynamic Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell 2000 Value-Defensive Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell 3000E Value Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell 2500 Value Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell Small Cap Comp Value Index
CI
06/25INNOVIVA, INC.(NASDAQGS : INVA) added to Russell 2000 Value Index
CI
05/26INNOVIVA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
News in other languages on INNOVIVA, INC.
09/15Les actions du secteur de la santé réduisent leurs gains initiaux alors que les produit..
05/21GSK : solde sa participation dans Innovia pour 392 M$
More news
Analyst Recommendations on INNOVIVA, INC.
More recommendations
Chart INNOVIVA, INC.
Duration : Period :
Innoviva, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNOVIVA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 15,93 $
Average target price 10,00 $
Spread / Average Target -37,2%
Managers and Directors
Pavel Raifeld Chief Executive Officer
George W. Bickerstaff Chairman
Jules Haimovitz Independent Director
Sarah J. Schlesinger Independent Director
Mark A. Dipaolo Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INNOVIVA, INC.28.57%1 107
JOHNSON & JOHNSON4.26%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY45.14%220 979